On 1 March 2018, the U.S. Food and Drug Administration (FDA) announced guidance for Good Clinical Practice (GCP), entitled “E6(R2) Good Clinical Practice: Integrated Addendum to E6(R1).” This guidance represents the current thinking of the FDA.

This integrated addendum guideline was collaboratively developed by the International Council for Harmonisation with input from the FDA. ICH E6(R2) “discusses approaches to clinical trial design, conduct, oversight, recording, and reporting as well as updated standards regarding electronic records and essential documents.”


CITI Program GCP courses reflect FDA guidance

CITI Program’s GCP modules reflect that the FDA has published ICH E6(R2) as guidance. The modules were previously revised to reflect the Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) updated guideline.


CITI Program has a free resource on the ICH E6(R2) integrated addendum

This resource is available on CITI Program’s Resources page. This resource was revised to reflect the FDA guidance.

This resource covers the revisions to the International Council for Harmonistion (ICH) “Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6 (R2),” including a breakdown by sections with summaries and analyses. The revised ICH E6(R2) guideline includes changes that affect sponsors, researchers, and IRBs.


Return to May 2018 Newsletter